{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:06:25Z","timestamp":1768802785136,"version":"3.49.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T00:00:00Z","timestamp":1608595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["015469"],"award-info":[{"award-number":["015469"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["021039"],"award-info":[{"award-number":["021039"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["CRUK\/07\/025"],"award-info":[{"award-number":["CRUK\/07\/025"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001111","name":"Cancer Australia","doi-asserted-by":"publisher","award":["APP1006602"],"award-info":[{"award-number":["APP1006602"]}],"id":[{"id":"10.13039\/501100001111","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ACTRN1261000016003"],"award-info":[{"award-number":["ACTRN1261000016003"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["ISRCTN68510403"],"award-info":[{"award-number":["ISRCTN68510403"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["NCT00532194"],"award-info":[{"award-number":["NCT00532194"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.esmoop.2020.100043","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T01:10:15Z","timestamp":1613610615000},"page":"100043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial"],"prefix":"10.1016","volume":"6","author":[{"given":"J.A.","family":"Ledermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.C.","family":"Embleton-Thirsk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.J.","family":"Perren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.C.","family":"Jayson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.J.S.","family":"Rustin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.B.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Hirte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Oza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Vaughan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Deane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Popoola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Farrelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.M.","family":"Swart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.S.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.K.B.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2020.100043_bib1","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2020.100043_bib2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib3","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A\u00a0phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2020.100043_bib4","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib5","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib6","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2020.100043_bib7","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel\u2013carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib8","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/0008-5472.CAN-04-4409","article-title":"AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer","volume":"65","author":"Wedge","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2020.100043_bib9","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib10","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1200\/JCO.2012.42.6031","article-title":"Cediranib plus FOLFOX\/CAPOX versus placebo plus FOLFOX\/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II)","volume":"30","author":"Hoff","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib11","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(15)00139-4","article-title":"Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial","volume":"16","author":"Valle","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.ejca.2011.12.022","article-title":"Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study","volume":"48","author":"Mulders","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2020.100043_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1200\/JCO.2009.22.9427","article-title":"Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study","volume":"28","author":"Goss","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib14","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1200\/JCO.2009.26.3988","article-title":"Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma","volume":"28","author":"Batchelor","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib15","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1200\/JCO.2012.47.4288","article-title":"Cediranib for metastatic alveolar soft part sarcoma","volume":"31","author":"Kummar","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib16","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","article-title":"Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"387","author":"Ledermann","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2020.100043_bib18","series-title":"Annual Report","year":"2011"},{"key":"10.1016\/j.esmoop.2020.100043_bib19","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/bjc.2011.334","article-title":"Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer","volume":"105","author":"Raja","year":"2011","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2020.100043_bib20","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib21","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1016\/S0140-6736(03)13718-X","article-title":"Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4\/AGO-OVAR-2.2 trial","volume":"361","author":"Parmar","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2020.100043_bib22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.ejca.2013.11.032","article-title":"Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC clinical trials group study BR29","volume":"50","author":"Laurie","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.esmoop.2020.100043_bib23","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1200\/JCO.2012.47.2464","article-title":"Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma","volume":"31","author":"Batchelor","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib24","series-title":"Withdrawal Assessment Report \u2013 Zemfirza","year":"2016"},{"key":"10.1016\/j.esmoop.2020.100043_bib25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/biomet\/81.3.515","article-title":"Proportional hazards tests and diagnostics based on weighted residuals","volume":"81","author":"Grambsch","year":"1994","journal-title":"Biometrika"},{"key":"10.1016\/j.esmoop.2020.100043_bib26","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.4274","article-title":"The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt","volume":"30","author":"Royston","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.esmoop.2020.100043_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12874-016-0110-x","article-title":"Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated","volume":"16","author":"Royston","year":"2016","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.esmoop.2020.100043_bib28","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13063-019-3251-5","article-title":"Combined test versus logrank\/Cox test in 50 randomised trials","volume":"20","author":"Royston","year":"2019","journal-title":"Trials"},{"key":"10.1016\/j.esmoop.2020.100043_bib29","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/1536867X1701700209","article-title":"A\u00a0combined test for a generalized treatment effect in clinical trials with a time-to-event outcome","volume":"17","author":"Royston","year":"2017","journal-title":"Stata J"},{"key":"10.1016\/j.esmoop.2020.100043_bib30","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1177\/1740774519862528","article-title":"Impact of retrospective data verification to prepare the ICON6 trial for use in a marketing authorization application","volume":"16","author":"Embleton-Thirsk","year":"2019","journal-title":"Clin Trials"},{"key":"10.1016\/j.esmoop.2020.100043_bib31","series-title":"Withdrawal Letter: Zemfirza","author":"AstraZeneca","year":"2016"},{"key":"10.1016\/j.esmoop.2020.100043_bib32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib33","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1200\/JCO.19.01009","article-title":"Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer","volume":"37","author":"Tewari","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib34","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmoop.2020.100043_bib35","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/AOG.0000000000003086","article-title":"Nomogram for predicting individual survival after recurrence of advanced-stage, high-grade ovarian carcinoma","volume":"133","author":"Rose","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.esmoop.2020.100043_bib36","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1002\/cncr.29082","article-title":"Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials: Intermediate Clinical Endpoints","volume":"121","author":"Matulonis","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2020.100043_bib37","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","article-title":"Incorporation of pazopanib in\u00a0maintenance therapy of ovarian cancer","volume":"32","author":"du Bois","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib38","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","article-title":"Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"17","author":"du Bois","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib39","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S1470-2045(14)70391-2","article-title":"Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study","volume":"15","author":"Liu","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib40","doi-asserted-by":"crossref","first-page":"eaav4508","DOI":"10.1126\/scitranslmed.aav4508","article-title":"Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1\/2 and RAD51","volume":"11","author":"Kaplan","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.esmoop.2020.100043_bib41","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1200\/JCO.2020.38.15_suppl.6003","article-title":"A\u00a0phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer","volume":"38","author":"Liu","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100043_bib42","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1002\/cncr.30657","article-title":"Quality of life with cediranib in relapsed ovarian cancer: the ICON6 phase 3 randomized clinical trial: quality of life in the ICON6 Trial","volume":"123","author":"Stark","year":"2017","journal-title":"Cancer"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920329094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920329094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:24:16Z","timestamp":1761855856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920329094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S2059702920329094"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2020.100043","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2020.100043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100043"}}